BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 32612616)

  • 1. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6: Relevance for immunopathology of SARS-CoV-2.
    Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
    Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus shifts to antibody cocktails for COVID-19 cytokine storm.
    Harrison C
    Nat Biotechnol; 2020 Aug; 38(8):905-908. PubMed ID: 32760027
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
    Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
    Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release syndrome in severe COVID-19.
    Moore JB; June CH
    Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
    [No Abstract]   [Full Text] [Related]  

  • 11. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
    Magro G
    Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
    Liu B; Li M; Zhou Z; Guan X; Xiang Y
    J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
    Nile SH; Nile A; Qiu J; Li L; Jia X; Kai G
    Cytokine Growth Factor Rev; 2020 Jun; 53():66-70. PubMed ID: 32418715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.